Get started
AbbVie Inc.AA

AbbVie Inc.

186.11USDR
+0.49+0.26%
At close at May 30, 23:57 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

ABBV trade ideas

$ABBV Breakout About AbbVie, Inc. AbbVie, Inc. is a leading biopharmaceutical company developing and selling treatments for various serious health conditions. Here's a brief overview: * Founded on October 19, 2011 * Headquartered in North Chicago, IL * Focus areas include: + Chronic autoimmune diseases (rheumatology, gastroenterology, dermatology) + Oncology (blood cancers, virology) + Neurological disorders (Parkinson's, metabolic disorders) + Other serious health conditions (HCV, HIV, endometriosis, cystic fibrosis) AbbVie is committed to improving patient outcomes through innovative research and development.
NLong
by ImmaculateTony
AbbVie Faces Humira Headwinds: Stock Dips 4.76%AbbVie Inc. ( NYSE:ABBV ) struggles with declining sales volumes of its blockbuster arthritis drug, Humira. Despite a positive outlook for its newer immunology treatments, Skyrizi and Rinvoq, concerns over the impact of biosimilar competition and shifting patient preferences have cast a shadow over the pharmaceutical giant's performance, leading to a dip in its stock price. Humira Volume Erosion Worries Weigh on AbbVie AbbVie's forecast of a 32% decline in U.S. Humira sales for the second quarter has sent ripples through the market, with investors expressing apprehension over the escalating erosion of the drug's market share. The introduction of biosimilars and changes by U.S. pharmacy benefit managers have contributed to the anticipated decline, prompting AbbVie ( NYSE:ABBV ) to brace for a challenging road ahead. Navigating the Biosimilar Landscape Despite the onslaught of biosimilar competition, AbbVie ( NYSE:ABBV ) remains steadfast in its efforts to retain market dominance, emphasizing its ability to retain the majority of the Humira market. However, concerns linger as health insurer Cigna's plans to offer biosimilar alternatives without out-of-pocket payments threaten to further impact Humira's volume, adding to the company's woes. Focus on Skyrizi and Rinvoq In light of the Humira sales decline, AbbVie ( NYSE:ABBV ) has intensified its focus on promoting its newer immunology treatments, Skyrizi and Rinvoq, as key drivers of future growth. The company's raised annual profit forecast reflects confidence in the performance of these drugs, which have demonstrated strong sales in the first quarter, surpassing analyst expectations. Strategic Adjustments Amidst Uncertainty AbbVie's proactive measures to address the challenges posed by Humira's erosion underscore its commitment to resilience and adaptability in the face of market headwinds. With a revised profit forecast and robust sales performance of Skyrizi and Rinvoq, AbbVie remains poised to weather the storm and emerge stronger, reaffirming its position as a leading player in the pharmaceutical industry. Conclusion: AbbVie's outlook amidst the backdrop of Humira volume erosion reflects the dynamic nature of the pharmaceutical landscape, where innovation and adaptability are essential for long-term success. As the company continues to navigate through challenges posed by biosimilar competition and shifting market dynamics, its strategic focus on newer treatments and proactive measures will be critical in shaping its trajectory in the months ahead.
NShort
by DEXWireNews
ABBV - Are you Ready?Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst. 📈ABBV has been in a correction phase and it is currently approaching the lower bound of the red and blue channels. Moreover, the green zone is a strong round number $150 and structure! 🏹 Thus, the highlighted blue circle is a strong area to look for buy setups as it is the intersection of structure and lower trendlines acting as non-horizontal support. 📚 As per my trading style: As #ABBV approaches the blue circle, I will be looking for bullish reversal setups (like a double bottom pattern, trendline break , and so on...) 📚 Always follow your trading plan regarding entry, risk management, and trade management. Good luck! All Strategies Are Good; If Managed Properly! ~Rich
N
by TheSignalyst
3
Major Price Movement Incoming for ABBV!Signalist has detected a precise pattern in NYSE:ABBV FUBO trading activity, signaling that a substantial price movement is imminent. This isn’t a random fluctuation—it’s a carefully analyzed precursor to a significant market event. 📅 What to Expect: ⌛ Timeline: Anticipate a major move within the next 1 to 4 upcoming 3-hour candles. 📈 Monitor the Charts: Keep an eye on ABBV’s price action over the next few candles. Prepare Your Strategy: Whether you’re bullish or bearish, have your trading plan ready to capitalize on the move.
N
by SIGNALIST_indicator
Leaning Bullish on ABBV after Strong Reaction to EarningsABBV had a solid reaction to earnings. The tight consolidation over the last few days supports a bullish momentum holding up. Volume declining over the last few days (when price has been declining) typically means a healthy consolidation before a continued rise. While the price may/may not continue down a bit more, if it starts to climb back up, the 201 area would be a place I'd consider an entry (either call option or stock). I'd place a stop around 194, and a first profit target when the price extends again from its 10EMA. That area of 201 for entry will be where the price rises above the moving averages on the 15m and 1h chart time frames, and the 10EMA crossing back above the 20EMA on the 15m timeframe. 1h
NLong
by emanuelaelias
3
ABBVIE broke below the 1D MA50. Confirmed sell opportunity.AbbVie Inc. (ABBV) has been trading within a Channel Up pattern since the November 09 2023 Low. Having made a Higher High on September 04 and been rejected at the top of the Channel Up, the price broke and closed aggressively below its 1D MA50 (blue trend-line) three days ago. That is a confirmed technical sell signal. The 1D RSI has been on Lower Highs before the actual High, very similar to the previous top on March 12 2024. That sequence, after breaking below its 1D MA50, extended aggressively towards the 1D MA200 (orange trend-line) and bottomed on the 0.618 Fibonacci retracement level. As a result, we can take a low risk sell now and target a potential contact with the 1D MA200 at $180.00. As far as buying the dip for the long-term is concerned, the most consistent buy signal has been the 1D RSI Bullish Divergence when it forms the first Higher Lows sequence after breaking below the 30.00 oversold barrier. So far that has worked 3 times almost perfectly, with the only exception the May 29 2024 bottom, which still was formed not that far away from the April 26 buy signal. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NShort
by TradingShot
2
ABBV ZonesAll rectangles are potential zones of influence for support/resistance pressure. Same applies to the 2 curves. 1st, I don't know if the red will prove to offer more resistance to the price as initially suspected, or failing and triggering a penetration. 2nd, even if it does prove to be a resistance force zone, don't know if the price will manage to squeeze between it and the purple I am a little bearish biased for now as the project also suggests with the descending rectangles, but will be following the price action especially near any of the elements in the design, to watch out for any rebounds from these shapes. If the situation changes I might add other rectangles especially on the upside which is not covered, in case the earnings push this in bullish territory, but we might not need them.
N
by UnknownUnicorn903284
ABBV Comprehensive analysisChart Analysis: 1. Asset: AbbVie Inc. (ABBV) on NYSE 2. Timeframe: 1-hour chart 3. Date Range: August 2023 to September 2024 (future projection) Price Action and Trend Analysis: The chart shows a bullish trend from August 2023 to June 2024, with the price rising from around $150 to a peak of about $170. There are several notable features: 1. Strong upward momentum from November 2023 to January 2024. 2. Consolidation phase from January to May 2024. 3. Recent breakout to new highs in June 2024. Support and Resistance Levels: - Major support: $155.12 - Minor support: $163.60 - Current resistance/sell point: $170.83 - Previous resistance turned support: $165.21 Volume Analysis: Without clear volume bars, it's challenging to make a definitive volume-based analysis. However, the presence of multiple long and short positions indicated on the chart suggests active trading periods. Technical Indicators: RSI-VWAP Indicator (17, 19, 80) is visible at the bottom of the chart, currently reading 57.20. This indicates: 1. The asset is not overbought or oversold (neutral territory). 2. There's still potential for upward movement before reaching overbought conditions. Trading Strategy and Projections: The chart includes a projected trading strategy with the following key points: 1. Current price: $170.83 2. Sell Point identified at the current price level 3. Projected price movement: A decline followed by a period of consolidation 4. Take Profits level: Around $155.12 Risk and Reward Scenario: - Potential Reward: If the projected decline occurs, there's a potential for a 9.2% return from the current price to the Take Profits level. - Risk: The asset is at all-time highs, which could lead to continued bullish momentum, invalidating the short-term bearish projection. Trading Opportunities: 1. Short-term Short Position: - Entry: Current price ($170.83) - Stop Loss: Above recent high (e.g., $172.00) - Take Profit: $155.12 - Risk-Reward Ratio: Approximately 1:3 2. Long-term Long Position: - Entry: At support level ($163.60 or $155.12) - Stop Loss: Below the entered support level - Take Profit: New all-time highs above $171.00 Anomalies and Divergences: The rapid price increase from May to June 2024 without a clear consolidation phase might indicate potential overextension of the bullish trend. Conclusion: ABBV shows a strong overall uptrend but appears to be at a critical juncture. The chart suggests a potential short-term bearish move, followed by consolidation. However, traders should be cautious of the overall bullish trend and the possibility of continued upward movement. Risk Management: Always use proper position sizing and stop-loss orders. The volatile nature of this asset, as evidenced by large price swings, necessitates strict risk management. Note: This analysis is based solely on the technical aspects visible in the provided chart. Fundamental analysis and broader market conditions should also be considered before making any trading decisions.
NShort
by Trustscore
ABBV - Increase in Probability of ValuationAlignment and compression of fibo clouds within the 15min to Daily spectrum signal an entry of direction and strength towards the first target. Proper management with partial achievement of the first target could authorize the search for the second target with reduced risk in the operation. Follow us if you want to receive new analyses and updates on this and other markets, including cryptocurrencies in different time frames. You can check out other recent studies by clicking on our profile. Have a good week!
NLong
by EthosInvest